Open Access

Predictors of immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma: a case report

  • Anna Maria Cattelan1,
  • Adriana Mattiolo2,
  • Angela Grassi2,
  • Maria Assunta Piano2,
  • Lolita Sasset3,
  • Marco Trevenzoli4,
  • Paola Zanovello5 and
  • Maria Luisa Calabrò2Email author
Infectious Agents and Cancer201611:5

https://doi.org/10.1186/s13027-016-0051-3

Received: 26 October 2015

Accepted: 21 January 2016

Published: 3 February 2016

Abstract

We present here a case of immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma (KS-IRIS) developed in an AIDS patient two months after initiation of antiretroviral therapy (ART). Baseline characteristics of this IRIS-KS case, within a cohort of 12 naïve AIDS-KS patients, were analyzed. No statistically significant differences in CD4 cell counts, plasma HIV RNA load, KS clinical staging, human herpesvirus 8 (HHV8) antibody titers and HHV8 load in peripheral blood mononuclear cells and saliva were evidenced. HHV8 load in plasma was found to be significantly higher in the KS-IRIS patient (> 6 log10 genome equivalents/ml, p = 0.01, t–test) compared to the 11 patients with KS regression. This case highlights that measurement of HHV8 load in plasma may be useful to identify patients at risk for KS-IRIS, and that this parameter should be included in the design of larger studies to define KS-IRIS risk predictors.

Keywords

Immune reconstitution inflammatory syndromeIRISKaposi’s sarcomaKSKS-IRISHHV8KSHVBiomarker

Introduction

Although it was initially reported in HIV-negative patients, the immune reconstitution inflammatory syndrome (IRIS) occurs more frequently in HIV-infected patients initiating antiretroviral therapy (ART). IRIS results from restored immunity causing an exaggerated inflammatory response against persistent infectious or non-infectious antigens [15] and occurs with a wide spectrum of clinical manifestations. IRIS may cause worsening of previously treated infections, tumor progression in patients with proliferative disorders, or unmasking of subclinical infections, with tumor development in patients co-infected with an oncogenic virus. One of the parameters predictive of IRIS is severe CD4 cell lymphopenia prior to ART initiation (< 50 cells/μl). Other relevant biomarkers are the elevated antigenic burden of an opportunistic infection and a decrease of at least more than 1 log10 HIV RNA in plasma, which represents one of the major criteria for the definition of IRIS [1, 2, 5].

A subset of patients (6–20 %) co-infected with human herpesvirus 8 (HHV8) may develop Kaposi’s sarcoma (“unmasking” Kaposi’s sarcoma-associated IRIS, KS-IRIS) or experience acute worsening of pre-existing tumor (“paradoxical” KS-IRIS) within a short interval (2–3 months) after ART initiation. The clinical course of KS-IRIS varies greatly according to the analyzed population, as demonstrated by Letang et al. [6] in a pooled analysis of 436 AIDS-KS patients initiating ART from two distinct geographical areas, UK and sub-Saharan Africa. KS-IRIS can be self-limiting in well-resourced countries, with a tendency to regress even without therapy readjustment. On the other hand, this condition is frequently associated with high mortality in sub-Saharan countries, reflecting the more advanced stage at presentation and the higher frequencies of comorbidities and coinfections in African populations. The study by Letang et al. [6] identified the following baseline biomarkers for risk stratification: ART alone as initial KS treatment, T1 KS clinical stage, and high plasma HIV RNA load (> 5 log10 copies/ml). Moreover, detectable baseline plasma HHV8 DNA was also found to predict KS-IRIS development in a subset of 259 patients, whereas quantification of plasma viral load showed no significant differences. However, the IRIS condition is characterized by an immunological disturbance in untreated AIDS-KS patients, leading to systemic activation of HHV8 lytic replication with subsequent viremia. Thus, baseline systemic viral burden might be useful for risk stratification, as previously demonstrated in IRIS associated with opportunistic infections and in AIDS-KS patients, in which a better clinical response was found to be correlated to a baseline plasma HHV8 load below 660 copies/ml [7].

Case report

A 39-year-old HIV-positive homosexual male was admitted to our Infectious Diseases Unit with asthenia and multiple (11) painless, nodular purple lesions concentrated in the trunk that ranged from 0.5 to 2.0 cm in the largest dimension. The patient was diagnosed with HIV infection and cutaneous Kaposi’s sarcoma was confirmed by histological examination. Either mucocutaneous and visceral involvement was excluded by endoscopic and neck, chest and abdominal computerized tomography (CT) examinations. The CD4 lymphocyte count was 360 cells/μl (14 %) and plasma HIV-1 RNA level was 4.09 log10 copies/ml. Parameters linked to HHV8 infection status, evaluated as previously reported [810], revealed active lytic replication, with high burden of cell-free viral progeny in plasma [6.16 log10 genome equivalents (GE)/ml] and saliva (4.95 log10 GE/ml, Table 1). The patient started a combined ART (cART) with darunavir/ritonavir plus coformulated tenofovir/emtricitabine. Four weeks after cART initiation, examination of the patient revealed stable cutaneous KS lesions; the CD4 lymphocyte count had increased to 810 cells/μl (20 %) and the plasma HIV RNA was undetectable (< log10 40 copies/ml). Within a further 4 week-treatment, the patient showed recrudescent KS, with an increased number of lesions (> 20 cutaneous lesions) and enlargement of pre-existing ones. CD4 cell count was 820 cells/ml (21 %) and HIV RNA viral load was under the limit of detectability. The sudden clinical KS worsening together with the rapid immunovirological response was indicative of an immune reconstitution inflammatory syndrome rather than KS progression. The patient continued the antiretroviral combination therapy and no systemic KS chemotherapy was administrated. KS-IRIS flare completely recovered in 10 months.
Table 1

Characteristics of the 12 male KS patients at study entry

 

KS-IRIS (N = 1)

KS (N = 11)a

Demographics

 

Median (IQR)

 Age (years)

39

35 (31.5–53)

Risk factor

 

N

 Homosexual transmission

1

9

 Bisexual transmission

 

1

 Heterosexual transmission

 

1

KS staging

  

 T0I0S0

1

1

 T1I0S0

 

3

 T1I0S1

 

2

 T0I1S1

 

1

 T1I1S1

 

4

HIV- and HHV8-related parameters

 

Median (IQR)

 CD4 cell count (cells/μl)

360

190 (80–335)

 HIV plasma load (log10 copies/ml)

4.09

4.97 (3.89–5.31)

 HHV8 PBMC load (GE/105 cells)

76

100 (26.50–160.75)

 HHV8 plasma load (log10 GE/ml)

6.16b

3.48 (3.26–3.76)

 HHV8 saliva load (log10 GE/105 cells)

4.95

2.87 (1.84–4.14)

 HHV8 ORF65 antibodiesc

< 50

400 (100–800)

 HHV8 LANA antibodiesc

12,800

800 (250–4,800)

KS-IRIS Kaposi’s sarcoma-associated immune reconstitution inflammatory syndrome, KS Kaposi’s sarcoma, IQR interquartile range, HHV8 human herpesvirus 8, PBMC peripheral blood mononuclear cells, GE genome equivalents, ORF65 open reading frame 65, encoding for a structural protein expressed during the lytic phase, LANA latency-associated nuclear antigen. aIn the KS group, data are expressed as median (interquartile range) calculated on the measurable samples. bSignificantly higher in the KS-IRIS case vs. KS group (p = 0.01). To perform statistical analysis, samples in which HIV RNA (N = 2) could not be detected were assigned an arbitrary value of log1040, specimens in which HHV8 ORF65 antibodies (N = 3) were not detected an arbitrary value of 40, and those in which HHV8 GE were not detected (PBMC, N = 3; plasma, N = 1; saliva, N = 1) were assigned an arbitrary value of 5 (PBMC) or log105. cAntibody titers were determined using 1:50 as first dilution, and are expressed as reciprocal of the highest dilution giving a positive result

To test the usefulness of previously reported KS-IRIS predictors [6], we analyzed baseline characteristics of the preceding 11 consecutive cART-naïve AIDS-KS patients referring to the Infectious Diseases Units of Padova and Rovigo, and followed at the Veneto Institute of Oncology for HHV8 diagnostics. All 11 patients had histologically confirmed KS. They had initiated combined antiretroviral therapy (cART) showing immunovirological response, accompanied by KS regression (data not shown), during the first 3 months of follow-up. Baseline characteristics of all KS patients are reported in Table 1. In the KS group, data are expressed as median and interquartile range (25th–75th percentile) calculated on the measurable samples. To compare the values of different biomarkers of the KS-IRIS case to those of the KS group, the one-tailed Crawford and Howell t-test was used [11]. No statistically significant differences in CD4 cell counts, plasma HIV RNA load, KS clinical staging [12], HHV8 antibody titers and HHV8 load in PBMC were observed. Conversely, HHV8 load in plasma was measurable in 11 of 12 patients, and was found to be significantly higher in the KS-IRIS case (> 6 log10 GE/ml, p = 0.01) compared to those measured in patients with KS regression. Moreover, HHV8 load in saliva was higher, albeit not statistically significant (p = 0.09), in the KS-IRIS case (Table 1).

Discussion

These findings, although limited to a small cohort, indicate that plasma HHV8 DNA detectability may not be so informative, and are fully in line with previously published studies. Indeed, 78.4 % of ART-naïve AIDS-KS patients from Zimbabwe had measurable plasma load, with a baseline median value of 2.82 log10 copies/ml [6, 7]. Moreover, HHV8 viremia was detectable at study entry in more than 90 % of AIDS-KS patients belonging to the Chelsea and Westminster HIV cohort, one of the largest cohorts in Europe, with a baseline median HHV8 load ranging from 4.6 to 5 log10 copies/ml [13]. The same cohort was analyzed in the pooled analysis [6], and plasma HHV8 DNA detectability, determined only in 104 patients, dropped to 58.3 % in this selected population, as did the baseline median value (2.87 log10 copies/ml) of plasma HHV8 load. We think that these discrepancies might be due to different sensitivities in the quantitative techniques, if samples were independently reanalyzed, or to a unrecognized bias related to the selection of the 104 patients for the pooled analysis. Another population of AIDS-KS patients included in Letang et al. [6] is the Durban cohort, from South Africa [14]; about half of these samples (54/112) were analyzed in the pooled analysis, and 74.1 % of the samples have measurable plasma HHV8 load, with a baseline median value of 2.24 log10 copies/ml [6]. Therefore, most of the individual studies showed high frequencies of HHV8 detectability in plasma, as did our small cohort; these figures are far from the highest, measured or estimated, incidences of KS-IRIS in any analyzed population, indicating that the HHV8 detection per se cannot be a predictive parameter.

Conclusion

This case highlights that, in our small cohort, the measurement of baseline HHV8 load in plasma was useful to identify the patient who experienced a KS-IRIS. Therefore, we recommend including quantification of baseline parameters linked to HHV8 infection status, specifically measurement of HHV8 load in plasma and, possibly, in saliva, in the design of larger studies to define KS-IRIS predictors.

Consent

This study was evaluated and approved by the Ethical Committee of the Veneto Institute of Oncology (Protocol n. 14256), and written informed consent was obtained from study participants.

Abbreviations

ART: 

antiretroviral therapy

cART: 

combined ART

GE: 

genome equivalents

HAART: 

highly active antiretroviral therapy

HHV8: 

human herpesvirus 8

IQR: 

interquartile range

IRIS: 

immune reconstitution inflammatory syndrome

KS: 

Kaposi’s sarcoma

KS-IRIS: 

immune reconstitution inflammatory syndrome associated with KS

LANA: 

latency-associated nuclear antigen

ORF65: 

open reading frame 65

PBMC: 

peripheral blood mononuclear cells

Declarations

Acknowledgements

This study was supported by grants from Associazione Italiana per la Ricerca sul Cancro and Fondazione Cariverona (grant n. 6599). A.M. and M.A.P. were recipients of a Ricerca Corrente fellowship, Italian Ministry of Health (IMH). A.G. was the recipient of a fellowship from Centro Lincei Interdisciplinare “Beniamino Segre”, Accademia Nazionale dei Lincei. We thank Christina Drace for help in preparing the manuscript.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Infectious and Tropical Diseases, Azienda Ospedaliera and University of Padova
(2)
Immunology and Molecular Oncology, Veneto Institute of Oncology, IOV IRCCS
(3)
Infectious Diseases, ULSS 18 - Azienda Ospedaliera
(4)
Department of Infectious and Tropical Diseases, University of Padova, School of Medicine
(5)
Department of Surgery, Oncology and Gastroenterology, University of Padova

References

  1. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Bonham S, Meya DB, Bohjanen PR, Boulware DR. Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med. 2008;2(4):349–61.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS. 2010;5(6):504–10.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Feller L, Lemmer J. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. Infect Agent Cancer. 2008;3:1.PubMedPubMed CentralView ArticleGoogle Scholar
  5. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615–27.PubMedView ArticleGoogle Scholar
  6. Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS. 2013;27(10):1603–13.PubMedView ArticleGoogle Scholar
  7. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis. 2010;51(3):342–9.PubMedView ArticleGoogle Scholar
  8. Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, et al. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27(3):779–85.PubMedGoogle Scholar
  9. Cattelan AM, Calabro ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, et al. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr. 2001;28:44–9.PubMedGoogle Scholar
  10. Gasperini P, Barbierato M, Martinelli C, Rigotti P, Marchini F, Masserizzi G, et al. Use of a BJAB-derived cell line for isolation of human herpesvirus 8. J Clin Microbiol. 2005;43(6):2866–75.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Crawford JR, Howell DC. Comparing an individual’s test score against norms derived from small samples. The Clinical Neuropsychologist. 1998;12:482–6.View ArticleGoogle Scholar
  12. Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085–92.PubMedGoogle Scholar
  13. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS. 2009;23(13):1701–6.PubMedView ArticleGoogle Scholar
  14. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150–7.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© Cattelan et al. 2016

Advertisement